Compare Funko Inc (FNKO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Funko Inc trades at $6.49 (market cap $363.97M), while State Street SPDR S&P Biotech ETF trades at $154.01 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 27.8× Funko Inc's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 1,422,651). Which is the better fit depends on your goals.
| FNKO | XBI | |
|---|---|---|
Market Cap | $363.97M | $10.11B |
Volume | 1,422,651 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $7.10 | $169.55 |
52-Week Low | $2.81 | $104.99 |
Typical Hold Time | 33 Days | — |
Enterprise Value | $584.62M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.525, up 3.41% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue declined to $908.21M in 2025, but Q2 2026 results showed 7% sales growth and improved EBITDA margins. The company maintains a low P/S ratio of 0.38 and reduced debt, while analyst consensus is a 'Hold' with a $7.58 price target.
The outlook is cautiously optimistic; valuation appears attractive, but negative net income and volatile cash flows pose risks. Upside depends on sustained EBITDA growth and execution of the 'Make Culture POP' strategy, while competitive pressures and consumer spending trends remain key watchpoints for investors.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
